CA-VELODYNE-LIDAR,-INC.
Velodyne Lidar, Inc. (Nasdaq: VLDR, VLDRW) will demonstrate its innovative lidar technologies at IAA Mobility (Hall B3, Booth A75) from Sept. 7 to 12 in Munich. Velodyne will display its technology leadership and product breadth in lidar sensors and software. Velodyne’s solutions power autonomous applications that advance safe, sustainable and accessible mobility, infrastructure and security.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210902005892/en/
Velodyne is hosting a press event at its IAA Mobility booth on Sept. 6 at 1:15 to 1:30 p.m. Velodyne executives will highlight how Velodyne´s solutions deliver the performance, range and reliability to power customers’ next-generation infrastructure and mobile applications. They will also discuss Velodyne’s portfolio of compact, solid-state sensors, which are embeddable for sleek, stylish integration into vehicles and robotics applications.
“At IAA Mobility, we will show how Velodyne’s sensors and software meet a wide range of customer needs to power safe mobility and smart city infrastructure globally,” said Erich Smidt, Vice President of Europe, Velodyne Lidar. “We will also have partners in our stand that are at the forefront in bringing to market the future of autonomous solutions. NI and Seoul Robotics are both recognized leaders in delivering high-quality solutions with the goal of improving people’s lives and increasing safety in our communities.”
Partners Showcase Lidar-Based Solutions
NI , developer of automated test and automated measurement systems, will co-exhibit at the Velodyne booth. NI will show simulations optimized for Velodyne’s lidar sensors that can be used in developing and testing advanced driver assistance systems (ADAS) and autonomous vehicle (AV) capabilities. NI simulation solutions make it easier to integrate Velodyne’s sensors into vehicle solutions, providing faster time to market and improving vehicle safety. NI will demonstrate how its monoDrive AV simulation software is using Velodyne’s lidar technology to create digital twins and is providing validated physics-based sensor models for Velodyne lidar sensors.
“Our ADAS and lidar simulation capabilities support faster system development and deployment of ADAS and AV solutions that use Velodyne’s sensors. The NI monoDrive Real-to-Virtual technology provides an end-to-end solution for collecting real-world data from cameras, lidars and GNSS systems to create high-fidelity digital twins that help to accelerate ADAS and AV development,” said Jeff Phillips, Director of Marketing for NI’s Transportation Business Unit. “The combination of Velodyne’s high-performance sensors and our simulation and validation capabilities allows developers to test and validate solutions in a massively scalable variety of conditions before they reach the road.”
Seoul Robotics , an Automated with Velodyne partner, will demonstrate at the Velodyne booth its AI perception engine for Velodyne’s lidar sensors which provides real-time object detection, classification, tracking and prediction for autonomous systems. The AI engine can power self-driving cars as well as smart city applications and advanced parameter monitoring systems for facilities. Seoul Robotics’ SENSR™ perception software includes an AI engine that is fully optimized to utilize Velodyne’s portfolio of lidar sensors, including the Puck™ , Ultra Puck™ and Alpha Prime™ .
Velodyne Highlights High Performance Sensors and Software
Among the Velodyne products showcased at IAA Mobility are:
Velarray H800 , a solid-state lidar sensor architected for automotive grade performance and built using Velodyne’s breakthrough proprietary micro-lidar array architecture (MLA). With combined long-range perception and a broad field of view, the sensor is designed for safe navigation and collision avoidance in ADAS and autonomous mobility applications. It can enable advanced driver assistance features such as Adaptive Cruise Control (ACC), Lane Keep Assist (LKA) and Pedestrian Automatic Emergency Braking (PAEB). The Velarray H800’s compact, embeddable form factor is designed to fit neatly behind the windshield of a truck, bus or car, or be mounted seamlessly on the vehicle exterior.
Velarray M1600 , an innovative solid-state lidar sensor designed to serve mobile robotic applications. The sensor is built using Velodyne’s MLA and provides outstanding near-field perception for safe navigation. The Velarray M1600 enables touchless mobile and last-mile delivery robots to operate autonomously and safely, without human intervention. This durable and compact sensor can be deployed in a wide variety of environments and weather conditions allowing nearly 365-day, 24/7 usage.
Velabit™ , Velodyne’s smallest sensor, which brings new levels of versatility and affordability to 3D lidar perception. This compact, mid-range lidar sensor is highly configurable for specialized use cases and can be embedded almost anywhere within vehicles, robots, unmanned aerial vehicles (UAVs) and infrastructure. The solid-state Velabit advances Velodyne’s mission to make high-quality 3D lidar sensors readily accessible to everyone.
Vella™ , Velodyne’s breakthrough ADAS software based on the directional view Velarray sensor. Vastly superior to existing approaches that utilize camera+radar, Vella will revolutionize advanced driver assistance functionalities currently on the market, including ACC, LKA and PAEB. The Vella Development Kit (VDK) enables companies to utilize the advanced capabilities of Vella software in their autonomous solutions. VDK helps companies use their development resources more efficiently by reducing the time and effort required to integrate 3D lidar sensors into applications.
About Velodyne Lidar
Velodyne Lidar (Nasdaq: VLDR, VLDRW) ushered in a new era of autonomous technology with the invention of real-time surround view lidar sensors. Velodyne, the global leader in lidar, is known for its broad portfolio of breakthrough lidar technologies. Velodyne’s revolutionary sensor and software solutions provide flexibility, quality and performance to meet the needs of a wide range of industries, including autonomous vehicles, advanced driver assistance systems (ADAS), robotics, unmanned aerial vehicles (UAV), smart cities and security. Through continuous innovation, Velodyne strives to transform lives and communities by advancing safer mobility for all. For more information, visit www.velodynelidar.com .
Forward Looking Statements
This press release contains “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995 including, without limitation, all statements other than historical fact and include, without limitation, statements regarding Velodyne’s target markets, new products, development efforts, and competition. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “can,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Velodyne’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include uncertainties regarding government regulation and adoption of lidar, the uncertain impact of the COVID-19 pandemic on Velodyne’s and its customers’ businesses; Velodyne’s ability to manage growth; Velodyne’s ability to execute its business plan; uncertainties related to the ability of Velodyne’s customers to commercialize their products and the ultimate market acceptance of these products; the rate and degree of market acceptance of Velodyne’s products; the success of other competing lidar and sensor-related products and services that exist or may become available; uncertainties related to Velodyne’s current litigation and potential litigation involving Velodyne or the validity or enforceability of Velodyne’s intellectual property; and general economic and market conditions impacting demand for Velodyne’s products and services. For more information about risks and uncertainties associated with Velodyne’s business, please refer to the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Risk Factors” sections of Velodyne’s SEC filings, including, but not limited to, its annual report on Form 10-K and quarterly reports on Form 10-Q. All forward-looking statements in this press release are based on information available to Velodyne as of the date hereof, Velodyne undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210902005892/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release
Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom